Navigation Links
Hospira Announces Positive Results From Phase I U.S. Clinical Trial of Biosimilar Erythropoietin in Renal Patients
Date:9/6/2011

LAKE FOREST, Ill., Sept. 6, 2011 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP), the world leader in generic injectable pharmaceuticals, today announced positive results from a Phase I U.S. clinical trial of its biosimilar erythropoietin (EPO) in patients with renal (kidney) dysfunction who have anemia. Hospira's trial met its key endpoint, showing equal pharmacokinetics, or blood level and distribution in the body, for Hospira's EPO and the reference product, Amgen's Epogen®. Erythropoietin is a treatment for anemia associated with chronic renal failure and chemotherapy.

The controlled, randomized trial of 100 patients on hemodialysis who had already been treated with Epogen took place at 20 different hemodialysis centers across the United States. Patients in the trial were treated with both Epogen and Hospira's EPO, with each patient receiving one drug first and then being switched to the second drug, spending one week on each. Besides showing equivalent pharmacokinetics, the trial showed no difference in patient safety between the two drugs, a secondary endpoint. The positive Phase I results pave the way for Hospira's planned Phase III U.S. program comparing safety and efficacy of the two products.

"The successful completion of our Phase I EPO trial is an important step for Hospira's U.S. biosimilars program," said Sumant Ramachandra, M.D., Ph.D., senior vice president, Research & Development and Medical & Regulatory Affairs, and chief scientific officer, Hospira. "We look forward to starting our Phase III U.S. program, and are committed to building on our success with biosimilars in Europe and Australia by making affordable, safe and effective biosimilars available to U.S. patients and their healthcare providers once patents expire over the next several years."

The first Phase III U.S. trial, scheduled to
'/>"/>

SOURCE Hospira, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Hospira to Host 2011 Investor Day
2. Hospira to Present at the Morgan Stanley Global Healthcare Conference
3. Hospira Expands Board of Directors
4. Hospira Announces U.S. Approval of Solution Version of Gemcitabine Injection
5. Hospira Reports Second-Quarter 2011 Results
6. Hospira to Host Conference Call for Second-Quarter 2011 Results
7. Hospira Receives Health Canada Regulatory Approval for Symbiq™ Infusion System Software Upgrade
8. Hospira to Present at the Sanford C. Bernstein Twenty-Seventh Annual Strategic Decisions Conference 2011
9. Hospira Highlights Progress in 2010 at Its 2011 Annual Meeting of Shareholders
10. Hospira Reports First-Quarter 2011 Results
11. Hospira Board Authorizes $1 Billion Share Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... , June 19, 2013   Voices Against Brain ... a cure for brain cancer, today announced that it ... to support the clinical investigation of Toca 511 & ... grade glioma brain cancer (Grade 3 or Grade 4).  ... treatments for advanced cancer, with an initial focus on ...
(Date:6/19/2013)... --  Nektar Therapeutics (Nasdaq: NKTR ) today ... study for NKTR-181, a first-in-class, opioid analgesic molecule ... slow rate of entry is designed to reduce the euphoria ... current opioid analgesics. 1 In the study data being ... in "drug liking" and "feeling high" scores and had highly ...
(Date:6/19/2013)... , June 19, 2013 NeuroDerm, ... study in volunteers, and preliminary results from a phase ... presented at the 2013 International Congress of Parkinson,s Disease ... drug formula under development for continuous administration through a ... plasma concentrations. ND0612 has been shown in ...
Breaking Medicine Technology:Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 2Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 2Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 4Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 5Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 6Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 7Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 8Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 9NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 2NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 3NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 4NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 5NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 6
... (Pink Sheets: SNDY) is pleased to announce that its ... at the 95th Annual American College of Surgeons Clinical ... the Breast Ductoscopy for the General Surgeon course, postgraduate ... skill stations that will provide the core knowledge base ...
... SAN RAMON, Calif., Oct. 7 Odyssey Thera, Inc. ... of its investors, Pfizer Inc. following Pfizer,s decision to ... of Odyssey,s multi-year alliance with Pfizer announced in August, ... to be earned for the advancement of specific drug ...
Cached Medicine Technology:Solos Endoscopy, Inc.'s MammoView(TM) Product Line to be Demonstrated at the 95th Annual American College of Surgeons Clinical Congress 2
(Date:6/19/2013)... June 19, 2013 Strict rules ... July 2013, Orriant is launching a new tool ... maintain compliance with regulations. New HHS regulations ... wellness incentives if their employer offers outcome-based, health-contingent, ... been compliant with these standards for nearly a ...
(Date:6/19/2013)... 19, 2013 As Januvia lawsuit ... to mount in courts throughout the U.S., Bernstein Liebhard ... (FDA) recently held a meeting to discuss the safety ... mimetics. According to a June 12th report from ... makers of Januvia and similar drugs, following a recent ...
(Date:6/19/2013)... what is believed to be the largest follow-up record ... dystonia a movement disorder that can cause crippling ... good success rates and lasting benefits. , Michele Tagliati, ... Cedars-Sinai Medical Center,s Department of Neurology, and Ron L. ... Beth Israel Deaconess Medical Center in Boston, published the ...
(Date:6/19/2013)... reveals significant disparities between minority and white clients ... programs. Moreover, these disparities vary widely from state ... for most states there,s something amiss," says Stephan ... "There are strong racial and ethnic disparities for ... treatment programs successfully, and those disparities are something ...
(Date:6/19/2013)... 2013 The Movement Disorders ... psychiatrists and urologists with specialists in physical therapy, ... with patients and their family members to manage ... life. Patients also have the opportunity to participate ... , “Movement disorders can be relentlessly progressive and ...
Breaking Medicine News(10 mins):Health News:New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations 2Health News:New Tool to Increase Participation Rates for Corporate Wellness Programs in July 2013 Will Help Maintain Compliance with Federal Regulations 3Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 2Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 3Health News:Long-term study reports deep brain stimulation effective for most common hereditary dystonia 2Health News:States vary widely on success rates for minorities in drug treatment programs 2Health News:States vary widely on success rates for minorities in drug treatment programs 3Health News:Abington Memorial Hospital’s Neurosciences Institute Opens Movement Disorders Center 2
... finds that almost half of the U.S. population possesses a ... of developing diabetes. // ,Diabetes is one of the ... many other complications. Genes are one among the many factors ... assistant professor of nutrition and dietetics at Doisy College of ...
... healthy eating habits, teens in middle adolescence are eating ... study reveals.// And the situation only worsens as teens ... important for the prevention of future chronic disease,” said ... it’s important to know whether intakes of teens are ...
... Louis University researcher confirms findings that about half of the ... them to metabolize food// differently, putting them at greater risk ... professor of nutrition and dietetics at Doisy College of Health ... version of a gene called FABP2, which is involved in ...
... the University of California, San Diego has found what ... promote cancer. The findings// may provide a new approach ... that what scientists thought were two distinct processes in ... dangers such as invading organisms—are actually linked. The researchers, ...
... Center-led study has shown conclusively that a neuropeptide, melanin ... for its role in// increasing appetite in people, plays ... and the secretion of insulin. This finding has the ... diabetes that stimulate the production of insulin-producing beta cells ...
... physicians predicts early risk of stroke following a serious condition ... a "mini-stroke," according to a study. ,About ... and about 70,000 in the United Kingdom. A TIA is ... oxygen supply to part of the brain that can cause ...
Cached Medicine News:Health News:Today’s Teens Slacking on Fruit, Veggie Intak 2Health News:Molecular Link Between Inflammation and Cancer Discovered 2Health News:Molecular Link Between Inflammation and Cancer Discovered 3Health News:Role of Appetite Hormone MCH in Insulin Production Revealed 2Health News:New Tool Improves Prediction of Stroke Risk 2
The Foundation PS knee offers a femoral option and tibial insert which provides a specially designed cam action that engages at 60 degrees of flexion to induce a smooth stable femoral roll-back motio...
... Natural Knee design includes several ... CSTi porous coating option for ... a unique bone preserving posterior ... groove to maximize range of ...
... Total Knee System provides anatomical replacement of ... while preserving the stabilizing Anterior and Posterior ... motion of the knee. All the components ... sizes and are equally proportioned and contoured ...
Advance Posterior Stabilized Total Knee systems improves patellofemoral kinematics, reduces wear rate potential, increases resistance to posterior tibial dislocation, achieves at least 120o flexion i...
Medicine Products: